Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China
PaperCitations, authors & open-access status
EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 94 citations, 2016 year and closed oa status.
94
Citations
2016
Year
closed
OA Status